Glucose Intolerance Clinical Trial
Official title:
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in Individuals With Impaired and Normal Glucose Tolerance
Dorzagliatin, a novel dual allosteric activator of glucokinase. reduces blood glucose by increasing insulin secretion by enhancing sensitivity of beta cells to glucose. In this placebo controlled cross over study, we examined the effects of dorzagliatin in people with impaired glucose tolerance and normal glucose tolerance.
Objective To investigate the acute effects of a single dose dorzagliatin on first phase insulin secretion and beta cell glucose sensitivity (βCGS) in individuals with impaired and normal glucose tolerance Methodology and rationale: A total of 20 subjects will be recruited, 10 in impaired glucose tolerant (IGT) and 10 in normal glucose tolerant (NGT) groups, respectively. Eligible participants will have a two-hour hyperglycemic clamp following a single dose of dorzagliatin or placebo in a randomized crossover fashion on V2 or V3. Subjects will be randomized to dorzagliatin 50mg or placebo in the IGT and NGT groups. Arterialized blood glucose (venous blood drawn from back of the hand placed in a temperature regulated box), measured every 5 minutes at the bedside Yellow Spring Instrument (YSI) or EKF glucose analyser, will be maintained at 12 mmol/l using an infusion of dextrose. Blood will be sampled for insulin and C-peptide at regular intervals for evaluation of first and second phase insulin secretion. Glucagon-like peptide-1 (GLP-1) and glucagon will be evaluated at regular intervals during the clamp studies. After 14 ± 2 days washout out (Day 14), participants will receive a single dose of dorzagliatin or matched placebo followed by a repeat hyperglycemic clamp to evaluate differences in beta-cell function. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT03675360 -
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
|
N/A | |
Completed |
NCT01671293 -
Multicomponent Telecare Model for Supporting Prediabetes Patients
|
N/A | |
Not yet recruiting |
NCT01402362 -
Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.
|
N/A | |
Completed |
NCT00740363 -
Sitagliptin in Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT00436475 -
Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04090788 -
The Effect of Momordica Charantia Supplementation on Blood Glucose Levels
|
N/A | |
Active, not recruiting |
NCT05460884 -
Effects of Seaweed Extract on Postprandial Response to White Bread
|
N/A | |
Not yet recruiting |
NCT05462834 -
Impact of Nocturnal Hypoxemia on Glucose in High Altitude Sleep Disordered Breathing
|
N/A | |
Completed |
NCT03348020 -
Iron and Insulin Resistance in Overweight and Obese Humans
|
N/A | |
Terminated |
NCT03356873 -
Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX)
|
N/A | |
Completed |
NCT03922685 -
Effects of Diet and Exercise on Circadian Glycemia
|
N/A | |
Completed |
NCT03730727 -
Exercise-meal Timing and Postprandial Glucose Control
|
N/A | |
Completed |
NCT04743960 -
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
|
N/A | |
Completed |
NCT04004273 -
Diabetes, Exercise and Liver Fat (DELIVER)
|
N/A | |
Terminated |
NCT01887691 -
Sleep Effectiveness and Insulin and Glucose Homeostasis
|
Phase 1 | |
Completed |
NCT02412995 -
The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite
|
Phase 0 | |
Not yet recruiting |
NCT01436448 -
Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy
|
Phase 3 |